These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 28295141)

  • 1. Adherence and Tolerability of Alzheimer's Disease Medications: A Pragmatic Randomized Trial.
    Campbell NL; Perkins AJ; Gao S; Skaar TC; Li L; Hendrie HC; Fowler N; Callahan CM; Boustani MA
    J Am Geriatr Soc; 2017 Jul; 65(7):1497-1504. PubMed ID: 28295141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication adherence and tolerability of Alzheimer's disease medications: study protocol for a randomized controlled trial.
    Campbell NL; Dexter P; Perkins AJ; Gao S; Li L; Skaar TC; Frame A; Hendrie HC; Callahan CM; Boustani MA
    Trials; 2013 May; 14():125. PubMed ID: 23782591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease.
    Cooke JR; Loredo JS; Liu L; Marler M; Corey-Bloom J; Fiorentino L; Harrison T; Ancoli-Israel S
    Drugs Aging; 2006; 23(6):503-11. PubMed ID: 16872233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation.
    Mohammad D; Chan P; Bradley J; Lanctôt K; Herrmann N
    Expert Opin Drug Saf; 2017 Sep; 16(9):1009-1019. PubMed ID: 28678552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
    López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
    Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].
    Sicras-Mainar A; Vergara J; Leon-Colombo T; Febrer L; Rejas-Gutierrez J
    Rev Neurol; 2006 Oct 16-31; 43(8):449-53. PubMed ID: 17033976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
    Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
    Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of washout and dose-escalation periods on the efficacy, safety, and tolerability of galantamine in patients previously treated with donepezil: ongoing clinical trials.
    Rasmusen L; Yan B; Robillard A; Dunbar F
    Clin Ther; 2001; 23 Suppl A():A25-30. PubMed ID: 11396868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability of Cholinesterase Inhibitors: A Population-Based Study of Persistence, Adherence, and Switching.
    Fisher A; Carney G; Bassett K; Dormuth CR
    Drugs Aging; 2017 Mar; 34(3):221-231. PubMed ID: 28138912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
    Rodda J; Morgan S; Walker Z
    Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
    Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
    Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
    Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R
    Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer's Disease and Parkinson's Dementia: Systematic Review and Meta-Analysis.
    Bittner N; Funk CSM; Schmidt A; Bermpohl F; Brandl EJ; Algharably EEA; Kreutz R; Riemer TG
    Drugs Aging; 2023 Nov; 40(11):953-964. PubMed ID: 37682445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug-cholinesterase-inhibitors persistence patterns in treated patients with dementia of Alzheimer type: retrospective comparative analysis of donepezil, rivastigmine and galantamine].
    Sicras A; Rejas-Gutiérrez J
    Rev Neurol; 2004 Aug 16-31; 39(4):312-6. PubMed ID: 15340887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
    Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
    J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of different acetylcholinesterase inhibitors on EEG patterns in patients with Alzheimer's disease: A systematic review.
    Arjmandi-Rad S; Vestergaard Nieland JD; Goozee KG; Vaseghi S
    Neurol Sci; 2024 Feb; 45(2):417-430. PubMed ID: 37843690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood pro-inflammatory cytokines in Alzheimer's disease in relation to the use of acetylcholinesterase inhibitors.
    Richardson C; Gard PR; Klugman A; Isaac M; Tabet N
    Int J Geriatr Psychiatry; 2013 Dec; 28(12):1312-7. PubMed ID: 23585364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of galantamine SA in dementia patients transitioned from donepezil.
    Rosenbloom MH; Brown J; Berlowitz DR; Budson AE
    Consult Pharm; 2011 Feb; 26(2):108-10. PubMed ID: 21310708
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.